Overview

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia

Status:
Unknown status

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficiency of adding pioglitazone to chronic phase chronic myelogenous leukemia patients having received imatinib mesylate who have acquired a stable molecular response but not complete molecular response.

Phase:

Phase 2

Details

Lead Sponsor:

Meng Li

Treatments:

Imatinib Mesylate
Pioglitazone